Table 2.
Comparison between HBcAb/HBsAb+/−-positive vs HBV-negative patient characteristics.
| Study population | HBcAb/HBsAb+/−-positive (n = 85) | HBV-negative (n = 136) | P-value |
|---|---|---|---|
| Age, years, median (IQR) | 48 (39–55) | 39 (29–48) | 0.0001 |
| Risk factors, n. (%) | |||
| Sexual | 68 (34%) | 125 (62.5%) | 0.01 |
| IDUs | 17 (54.8%) | 11 (35.5%) | 0.01 |
| Months from cART initiation, median (IQR) | 1.3 (0.6–4.9) | 1.4 (0.85–3.6) | 0.25 |
| Duration of cART, months, median (IQR) | 49.8 (29.3–84.7) | 49.4 (33.9–79) | 0.89 |
| Calendar years since cART start, median (IQR) | 2013 (2011–2015) | 2013 (2011–2015) | 0.58 |
| Follow-up, months, median (IQR) | 61.9 (34.8–92.3) | 56.3 (36.2–84.3) | 0.56 |
| AST, UI/L, median, (IQR) | 23 (18–34) | 21 (16–31.5) | 0.40 |
| ALT, UI/L, median, (IQR) | 32 (24–43) | 28 (21.5–40) | 0.02 |
| Platelet count, 106/µL median (IQR) | 191 (126–227) | 200 (164–256) | 0.02 |
| Flair of transaminases, median (IQR) | 56 (65,9%) | 49 (36%) | <0.0001 |
| FIB-4 at baseline, median (IQR) | 1.12 (0.68–1.81) | 0.76 (0.48–1.2) | 0.001 |
| Anti-HCV+, n. (%) | 7 (8.2%) | 5 (3.6%) | 0.23 |
| HCV-RNA-positive, n. (%) | 1 (1.1%) | 1 (0.7%) | nc |
| CD4+ at baseline, cell/mmc, median (IQR) | 188 (78–334) | 293 (127–443) | 0.02 |
| Pre-cART CD4+ cell/mmc, median (IQR) | 176 (52–284) | 239 (97–390) | 0.01 |
| Pre-cART HIV viremia, cp/mL median (IQR) | 109.8 (45.6–330.7) | 63 (22.4–241.1) | 0.14 |
| Undetectability at 6th month, median (IQR) | 50 (59.5%) | 115 (84.6%) | <0.0001 |
| Undetectability, months, median (IQR) | 6 (4–8) | 4 (3–6) | 0.0001 |
| AIDS-related events, Yes/No, n. (%) | 35 (41,1%) | 26 (19,1%) | 0.002 |
| Non-AIDS related events, Yes/No, n. (%) | 48 (56.5%) | 39 (28.7%) | <0.0001 |
| cART anti-HBV active drugs, n. (%): | |||
| -Lamivudine | 14 (16.4%) | 22 (16.1%) | 0.95 |
| -Tenofovir/TAF | 62 (72.9%) | 106 (77.9%) | 0.66 |
| -No anti-HBV agent | 9 (10.6%) | 8 (5.9%) | 0.28 |
| Type of cART | |||
| PI + 2 NRTIs | 54 (39.7) | 42 (49.4) | 0.157 |
| NNRTI + 2 NRTI | 46 (33.8) | 25 (29.4) | 0.494 |
| INI + 2 NRTI | 31 (22.8) | 12 (14.1) | 0.113 |
| Other | 5 (3.7) | 6 (7.1) | 0.342 |
| >1 year without anti-HBV agent, n. (%) | 12 (14.3%) | 11 (8.1%) | 0.18 |
| HIV VR, median (IQR) | 18 (21.7%) | 14 (10.3%) | 0.06 |
| HIV VB, median (IQR) | 62 (74.7%) | 30 (22.1%) | <0.0001 |
| Deaths, n.(%) | 6 (7.1%) | 2 (1.5%) | 0.006 |
IDU: injecting drug users; cART: combined antiretroviral therapy; AST: aspartate aminotransferase; ALT: alanine aminotransferase; Undetectability: HIV-RNA < 50 copies/mL; TAF: Tenofovir alafenamide; VR: virological rebound; VB: HIV viral blips.